S&P Futures
5,887.50 -5.00 (-0.08%) Dow Futures
43,046.00 -123.00 (-0.28%) Nasdaq Futures
20,516.25 -25.75 (-0.13%) Russell 2000 Futures
2,246.50 +0.30 (+0.01%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,760.60 +0.80 (+0.03%)
Suven Life Sciences Limited (SUVEN.BO)
Suven Life Sciences Limited
8-2-334, SDE Serene Chambers
6th Floor Road No.5, Avenue 7 Banjara Hills
Hyderabad 500034
India
91 40 2354 1142
https://www.suven.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 141
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Venkateswarlu Jasti M.Pharm. M.S. | CEO & Director | N/A | N/A | 1949 |
| Ms. Sudharani Jasti B.Sc. | Whole-Time Director | 9.99M | N/A | 1954 |
| Mr. Vivek Sharma CPA | Executive Chairman | N/A | N/A | N/A |
| Mr. M. Mohan Kumar C.M.A. | Chief Financial Officer | N/A | N/A | N/A |
| Mr. Kundan Kumar Jha | Company Secretary & Compliance Officer | N/A | N/A | N/A |
| Ms. Kalyani Jasti | President of US Operations | N/A | N/A | 1979 |
Description
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Corporate Governance
Suven Life Sciences Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
